Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
November 10 2008 - 1:04PM
PR Newswire (US)
WEIFANG, China, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Shengtai
Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI) ("Shengtai"
or "the Company"), a leading manufacturer and distributor of
high-quality, pharmaceutical grade glucose products in China, today
announced that it will issue financial results for the three months
ended September 30, 2008 after the close of the stock market on
Thursday, November 13, 2008. Management will conduct a conference
call on Friday, November 14, 2008 at 9:00 A.M. Eastern Standard
Time to discuss these results. A question and answer session will
follow management's presentation. Mr. Qingtai Liu (Chief Executive
Officer), Ms. Yiru Melody Shi (CFO), and Ms. Michelle Wang
(Investor Relations Manager) will be the primary speakers on the
call. A live webcast of the conference call will be available on
the Investor Relations page of Shengtai Pharmaceutical's web site
at http://www.shengtaipharmaceutical.com/ . Please visit the Web
site at least 15 minutes early to register for the webcast and
download any necessary audio software. To participate, please call
the following numbers ten minutes before the call start time: Phone
Number: +1-877-407-8035 (North America) Phone Number:
+1-201-689-8035 (International) A replay of the call will be
available through Friday, November 21, 2008, at 11:59 P.M. Eastern
Standard Time. For the replay, please call: Phone Number:
+1-877-660-6853 (North America) Phone Number: +1-201-612-7415
(International) Account Number: 286 Conference ID Number: 302820
About Shengtai Pharmaceutical, Inc. Shengtai Pharmaceutical, Inc.
through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI),
a New Jersey corporation, and the Chinese operating company of
Weifang Shengtai Pharmaceutical Co., Ltd., is a leading
manufacturer and supplier of pharmaceutical grade glucose used for
medical purposes. It also manufactures and supplies glucose and
cornstarch products to the food, beverage and industrial production
industries in China. For more information about Shengtai
Pharmaceutical, Inc., please visit
http://www.shengtaipharmaceutical.com/ . Safe Harbor Statement
Certain statements in this press release and oral statements made
by the Company constitute forward-looking statements for purposes
of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. These statements include, without
limitation, statements regarding our ability to prepare the Company
for growth, the Company's planned capacity expansion in 2008 and
predictions and guidance relating to the Company's future financial
performance. We have based these forward-looking statements largely
on our current expectations and projections about future events and
financial trends that we believe may affect our financial
condition, results of operations, business strategy and financial
needs, but they involve risks and uncertainties that could cause
actual results to differ materially from those in the
forward-looking statements, which may include, but are not limited
to, such factors as unanticipated changes in product demand
especially in the pharmaceutical industry, pricing and demand
trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large-scale implementation of the
Company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the Company's expectations. For
further information, please contact: Shengtai Pharmaceutical, Inc.
Ms. Yiru Melody Shi Chief Financial Officer Tel: +1-949-468-7078
Email: Grayling Global Eddie Cheung Investor Relations Tel:
+1-646-284-9414 Email: DATASOURCE: Shengtai Pharmaceutical, Inc.
CONTACT: Ms. Yiru Melody Shi, Chief Financial Officer Shengtai
Pharmaceutical, Inc., +1-949-468-7078, ; or at Grayling Global,
Eddie Cheung, Investor Relations, +1-646-284-9414, , for SGTI Web
Site: http://www.shengtaipharmaceutical.com/
Copyright